Also trades as: XTLB (NASDAQ) · $vol 5M
XTLB.TA TLV
XTL Biopharmaceuticals Ltd.
1W: -5.0%
1M: +0.0%
3M: -32.1%
YTD: -32.1%
1Y: -59.6%
3Y: +4218.2%
5Y: +4900.0%
₪1.90 ($0.01)
+0.00 (+0.00%)
Weekly Expected Move ±30.4%
₪1
₪1
₪2
₪3
₪3
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Smart Money Score
No convergence signal
Key Statistics
Market Cap₪18.0M ($0.1M)
52W Range1.8-11.8
Volume7,280,250
Avg Volume4,395,906
Beta0.71
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEONoam Band
Employees10
SectorHealthcare
IndustryBiotechnology
IPO Date2005-08-30
Websitextlbio.com
5 Badner Street
Ramat Gan 5218102
IL
Ramat Gan 5218102
IL
972 3 611 6600
About XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Recent Insider Trades
No insider trades found